Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Nelarabine.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Nelarabine.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Nelarabine.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Nelarabine is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Nelarabine.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Nelarabine is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Nelarabine is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Nelarabine.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Nelarabine.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nelarabine.
Clozapine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Nelarabine.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Nelarabine.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Nelarabine.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Nelarabine.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Nelarabine.
Digoxin
Digoxin may decrease the cardiotoxic activities of Nelarabine.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Nelarabine.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine.
Fingolimod
Nelarabine may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Nelarabine is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Hepatitis B Vaccine (Recombinant).
Leflunomide
The risk or severity of adverse effects can be increased when Nelarabine is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Nelarabine.
Ouabain
Ouabain may decrease the cardiotoxic activities of Nelarabine.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nelarabine.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nelarabine.
Pentostatin
Pentostatin may decrease the antineoplastic activities of Nelarabine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nelarabine.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Nelarabine.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Nelarabine is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nelarabine.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Nelarabine.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Nelarabine is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Nelarabine is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Nelarabine is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nelarabine.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Nelarabine.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Nelarabine is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Nelarabine may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Nelarabine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Nelarabine is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Nelarabine is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Nelarabine is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Nelarabine is combined with Yellow Fever Vaccine.
